You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.
The company launched the RxMatch Antidepressant Panel as the first step to grow beyond precision oncology and offer genomic assays for a wider range of diseases.
An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.
Researchers from Hong Kong imputed transcriptomes from GWAS data and compared them to drug-induced gene expression profiles.
NBC News reports that pharmacogenomics can help match people with depression to drugs that may work best for them.
The study will combine cognitive assessments with genetic data and survey responses to gain insights into the causes of these two mental health conditions.
Researchers in Australia hope the genetic study will help take the guesswork out of prescribing medications for depression, the Hack says.
The international team of researchers also examined the genetic ties between personality traits and psychiatric disorders.
23andMe's database has enabled it to link loci to disease and fuel better understanding of diseases like depression, KQED Science says.
The company has recently launched its first diagnostic test on the market and is developing a second, which is currently in clinical trials.
President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.
Nature News writes that scientists are trying to figure out how to name the new strains of SARS-CoV-2 that are emerging.
The New York Times reports that researchers are studying identical twins who had COVID-19 to understand the influence of genetics on disease severity.
In PNAS this week: epistasis affecting cystic fibrosis, Tiger rattlesnake genome gives venom insight, and more.